Sanofi (NASDAQ: SNY): Q4 2019 Earnings Snapshot

— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018. — Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34. — IFRS net sales, on […]

$SNY February 6, 2020 1 min read

NYSE

$SNY · Earnings

“
— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018. — Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34. — IFRS net sales, on […]
· February 6, 2020

— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.

— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.

— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.

— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.

— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.

— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.

— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.

— SNY stock was up about 4% in the pre-market trading session.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Related Articles

Stock Futures Ease 0.3% With Real Estate-Heavy Earnings Calendar in Focus

DFIN’s Software Pivot Pays Off: High Margins and Recurring Revenue Lead the Way

Graham Corporation Expands Capabilities Across Defense, Energy, and Space Markets